Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

Antiangiogenic therapy resistance occurs frequently in patients with metastatic renal cell carcinoma (RCC). The purpose of this study was to understand the mechanism of resistance to sunitinib, an antiangiogenic small molecule, and to exploit this mechanism therapeutically. We hypothesized that suni...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncogene
Prif Awduron: Zhou, Lijun, Liu, Xian-De, Sun, Mianen, Zhang, Xuesong, German, Peter, Bai, Shanshan, Ding, Zhiyong, Tannir, Nizar, Wood, Christopher G, Matin, Surena F, Karam, Jose A, Tamboli, Pheroze, Sircar, Kanishka, Rao, Priya, Rankin, Erinn B., Laird, Douglas A, Hoang, Anh G, Walker, Cheryl L, Giaccia, Amato J, Jonasch, Eric
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4791213/
https://ncbi.nlm.nih.gov/pubmed/26364599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2015.343
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg